Adjuvant interferon-α therapy for melona: Statement by dermatological oncology study group (ADO);Adjuvante interferon-α-therapie beim melanom: Stellungnahme derarbeitsgemeinschaft dermatologische onkologie (ADO)

Hautarzt

Volumn 49, Issue 3, 1998, Pages 167-169

  Hauschild, A ^a   Dummer, R ^a   Garbe, C ^a   Kaufmann, R ^a   Schadendorf, D ^a   Soyer, H P ^a   Stadler, R ^a   Tilgen, W ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON ALFA-2B; MELANOMA; MULTICENTER STUDIES; NEOPLASM STAGING; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0031924123     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050050722     Document Type: Article

References (5)